APO Research
Talk to an analyst

APO RESEARCH · REPORT

Age Related Macular Degeneration Drug

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.

Selected research

Market Outlook & Growth Opportunities

Global Age Related Macular Degeneration Drug Market Outlook and Growth Opportunities 2026

22 December 2025191 pages

Choose your research edition.

Industry ResearchAge Related Macular Degeneration Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Age Related Macular Degeneration Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Age Related Macular Degeneration Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Age Related Macular Degeneration Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Age Related Macular Degeneration Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.

North America is the largest Age Related Macular Degeneration Drug market with about 65% market share. Europe is follower, accounting for about 29% market share.

The key players are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma etc. Top 3 companies occupied about 79% market share.

Read the full market overview

This report provides an overview of the global Age Related Macular Degeneration Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Age Related Macular Degeneration Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Age Related Macular Degeneration Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Age Related Macular Degeneration Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Age Related Macular Degeneration Drug Segment by Company

Regeneron Pharmaceuticals

Bayer HealthCare

Novartis

Roche

Kanghong Pharma

Age Related Macular Degeneration Drug Segment by Type

Lucentis

Eylea

Avastin

Others

Age Related Macular Degeneration Drug Segment by Application

Hospitals

Clinics

Others

Age Related Macular Degeneration Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Age Related Macular Degeneration Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Age Related Macular Degeneration Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Age Related Macular Degeneration Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Age Related Macular Degeneration Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age Related Macular Degeneration Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Age Related Macular Degeneration Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age Related Macular Degeneration Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Age Related Macular Degeneration Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Age Related Macular Degeneration Drug industry.

Chapter 3: Detailed analysis of Age Related Macular Degeneration Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Age Related Macular Degeneration Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Age Related Macular Degeneration Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Age Related Macular Degeneration Drug Industry Trends Table 2. Age Related Macular Degeneration Drug Industry Drivers Table 3. Age Related Macular Degeneration Drug Industry Opportunities and Challenges Table 4. Age Related Macular Degeneration Drug Industry Restraints Table 5. Global Age Related Macular Degeneration Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Age Related Macular Degeneration Drug Revenue Share by Company (2021-2026) Table 7. Global Age Related Macular Degeneration Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Age Related Macular Degeneration Drug Sales Volume Share by Company (2021-2026) Table 9. Global Age Related Macular Degeneration Drug Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Age Related Macular Degeneration Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Age Related Macular Degeneration Drug Key Company Manufacturing Base & Headquarters Table 12. Global Age Related Macular Degeneration Drug Company, Product Type & Application Table 13. Global Age Related Macular Degeneration Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Age Related Macular Degeneration Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Lucentis Table 18. Significant Companies of Eylea Table 19. Significant Companies of Avastin Table 20. Significant Companies of Others Table 21. Global Age Related Macular Degeneration Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Age Related Macular Degeneration Drug Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Age Related Macular Degeneration Drug Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Age Related Macular Degeneration Drug Sales Volume Share by Type (2021-2026) Table 25. Global Age Related Macular Degeneration Drug Sales Volume Share by Type (2027-2032) Table 26. Global Age Related Macular Degeneration Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Age Related Macular Degeneration Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Age Related Macular Degeneration Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Age Related Macular Degeneration Drug Sales Value Share by Type (2021-2026) Table 30. Global Age Related Macular Degeneration Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospitals Table 32. Significant Companies of Clinics Table 33. Significant Companies of Others Table 34. Global Age Related Macular Degeneration Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Age Related Macular Degeneration Drug Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Age Related Macular Degeneration Drug Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Age Related Macular Degeneration Drug Sales Volume Share by Application (2021-2026) Table 38. Global Age Related Macular Degeneration Drug Sales Volume Share by Application (2027-2032) Table 39. Global Age Related Macular Degeneration Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Age Related Macular Degeneration Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Age Related Macular Degeneration Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Age Related Macular Degeneration Drug Sales Value Share by Application (2021-2026) Table 43. Global Age Related Macular Degeneration Drug Sales Value Share by Application (2027-2032) Table 44. Global Age Related Macular Degeneration Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Age Related Macular Degeneration Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Age Related Macular Degeneration Drug Sales Market Share by Region (2021-2026) Table 47. Global Age Related Macular Degeneration Drug Sales by Region (2027-2032) & (K Units) Table 48. Global Age Related Macular Degeneration Drug Sales Market Share by Region (2027-2032) Table 49. Global Age Related Macular Degeneration Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Age Related Macular Degeneration Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Age Related Macular Degeneration Drug Sales Value Share by Region (2021-2026) Table 52. Global Age Related Macular Degeneration Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Age Related Macular Degeneration Drug Sales Value Share by Region (2027-2032) Table 54. Global Age Related Macular Degeneration Drug Market Average Price (USD/Unit) by Region (2021-2026) Table 55. Global Age Related Macular Degeneration Drug Market Average Price (USD/Unit) by Region (2027-2032) Table 56. Global Age Related Macular Degeneration Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Age Related Macular Degeneration Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Age Related Macular Degeneration Drug Sales by Country (2021-2026) & (K Units) Table 59. Global Age Related Macular Degeneration Drug Sales Market Share by Country (2021-2026) Table 60. Global Age Related Macular Degeneration Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Age Related Macular Degeneration Drug Sales Market Share by Country (2027-2032) Table 62. Global Age Related Macular Degeneration Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Age Related Macular Degeneration Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Age Related Macular Degeneration Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Age Related Macular Degeneration Drug Sales Value Market Share by Country (2027-2032) Table 66. Regeneron Pharmaceuticals Company Information Table 67. Regeneron Pharmaceuticals Business Overview Table 68. Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 69. Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Portfolio Table 70. Regeneron Pharmaceuticals Recent Development Table 71. Bayer HealthCare Company Information Table 72. Bayer HealthCare Business Overview Table 73. Bayer HealthCare Age Related Macular Degeneration Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 74. Bayer HealthCare Age Related Macular Degeneration Drug Product Portfolio Table 75. Bayer HealthCare Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Age Related Macular Degeneration Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 79. Novartis Age Related Macular Degeneration Drug Product Portfolio Table 80. Novartis Recent Development Table 81. Roche Company Information Table 82. Roche Business Overview Table 83. Roche Age Related Macular Degeneration Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 84. Roche Age Related Macular Degeneration Drug Product Portfolio Table 85. Roche Recent Development Table 86. Kanghong Pharma Company Information Table 87. Kanghong Pharma Business Overview Table 88. Kanghong Pharma Age Related Macular Degeneration Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 89. Kanghong Pharma Age Related Macular Degeneration Drug Product Portfolio Table 90. Kanghong Pharma Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Age Related Macular Degeneration Drug Distributors List Table 94. Age Related Macular Degeneration Drug Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Age Related Macular Degeneration Drug Product Image Figure 2. Global Age Related Macular Degeneration Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Age Related Macular Degeneration Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Age Related Macular Degeneration Drug Sales (2021-2032) & (K Units) Figure 5. Global Age Related Macular Degeneration Drug Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Age Related Macular Degeneration Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Lucentis Image Figure 10. Eylea Image Figure 11. Avastin Image Figure 12. Others Image Figure 13. Global Age Related Macular Degeneration Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Age Related Macular Degeneration Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Age Related Macular Degeneration Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Age Related Macular Degeneration Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Age Related Macular Degeneration Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Age Related Macular Degeneration Drug Sales Value Share by Type (2021-2032) Figure 19. Hospitals Image Figure 20. Clinics Image Figure 21. Others Image Figure 22. Global Age Related Macular Degeneration Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Age Related Macular Degeneration Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Age Related Macular Degeneration Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Age Related Macular Degeneration Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Age Related Macular Degeneration Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Age Related Macular Degeneration Drug Sales Value Share by Application (2021-2032) Figure 28. Global Age Related Macular Degeneration Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Age Related Macular Degeneration Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Age Related Macular Degeneration Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Age Related Macular Degeneration Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Age Related Macular Degeneration Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Age Related Macular Degeneration Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Age Related Macular Degeneration Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Age Related Macular Degeneration Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Age Related Macular Degeneration Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Age Related Macular Degeneration Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Age Related Macular Degeneration Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Age Related Macular Degeneration Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Age Related Macular Degeneration Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Age Related Macular Degeneration Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Age Related Macular Degeneration Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Age Related Macular Degeneration Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Lucentis
  • Eylea
  • Avastin
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Regeneron Pharmaceuticals
  • Bayer HealthCare
  • Novartis
  • Roche
  • Kanghong Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Age Related Macular Degeneration Drug Sales Value (2021-2032)
  4. 1.2.2 Global Age Related Macular Degeneration Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Age Related Macular Degeneration Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Age Related Macular Degeneration Drug Market Dynamics
  1. 2.1 Age Related Macular Degeneration Drug Industry Trends
  2. 2.2 Age Related Macular Degeneration Drug Industry Drivers
  3. 2.3 Age Related Macular Degeneration Drug Industry Opportunities and Challenges
  4. 2.4 Age Related Macular Degeneration Drug Industry Restraints
3 Age Related Macular Degeneration Drug Market by Company
  1. 3.1 Global Age Related Macular Degeneration Drug Company Revenue Ranking in 2025
  2. 3.2 Global Age Related Macular Degeneration Drug Revenue by Company (2021-2026)
  3. 3.3 Global Age Related Macular Degeneration Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Age Related Macular Degeneration Drug Average Price by Company (2021-2026)
  5. 3.5 Global Age Related Macular Degeneration Drug Company Ranking (2024-2026)
  6. 3.6 Global Age Related Macular Degeneration Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Age Related Macular Degeneration Drug Company Product Type and Application
  8. 3.8 Global Age Related Macular Degeneration Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Age Related Macular Degeneration Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Age Related Macular Degeneration Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Age Related Macular Degeneration Drug Market by Type
  1. 4.1 Age Related Macular Degeneration Drug Type Introduction
  2. 4.1.1 Lucentis
  3. 4.1.2 Eylea
  4. 4.1.3 Avastin
  5. 4.1.4 Others
  6. 4.2 Global Age Related Macular Degeneration Drug Sales Volume by Type
  7. 4.2.1 Global Age Related Macular Degeneration Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Age Related Macular Degeneration Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Age Related Macular Degeneration Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Age Related Macular Degeneration Drug Sales Value by Type
  11. 4.3.1 Global Age Related Macular Degeneration Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Age Related Macular Degeneration Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Age Related Macular Degeneration Drug Sales Value Share by Type (2021-2032)
5 Age Related Macular Degeneration Drug Market by Application
  1. 5.1 Age Related Macular Degeneration Drug Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Age Related Macular Degeneration Drug Sales Volume by Application
  6. 5.2.1 Global Age Related Macular Degeneration Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Age Related Macular Degeneration Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Age Related Macular Degeneration Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Age Related Macular Degeneration Drug Sales Value by Application
  10. 5.3.1 Global Age Related Macular Degeneration Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Age Related Macular Degeneration Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Age Related Macular Degeneration Drug Sales Value Share by Application (2021-2032)
6 Age Related Macular Degeneration Drug Regional Sales and Value Analysis
  1. 6.1 Global Age Related Macular Degeneration Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Age Related Macular Degeneration Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Age Related Macular Degeneration Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Age Related Macular Degeneration Drug Sales by Region (2027-2032)
  5. 6.3 Global Age Related Macular Degeneration Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Age Related Macular Degeneration Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Age Related Macular Degeneration Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Age Related Macular Degeneration Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Age Related Macular Degeneration Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Age Related Macular Degeneration Drug Sales Value (2021-2032)
  12. 6.6.2 North America Age Related Macular Degeneration Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Age Related Macular Degeneration Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Age Related Macular Degeneration Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Age Related Macular Degeneration Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Age Related Macular Degeneration Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Age Related Macular Degeneration Drug Sales Value (2021-2032)
  21. 6.9.2 South America Age Related Macular Degeneration Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Age Related Macular Degeneration Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Age Related Macular Degeneration Drug Sales Value Share by Country, 2025 VS 2032
7 Age Related Macular Degeneration Drug Country-level Sales and Value Analysis
  1. 7.1 Global Age Related Macular Degeneration Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Age Related Macular Degeneration Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Age Related Macular Degeneration Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Age Related Macular Degeneration Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Age Related Macular Degeneration Drug Sales by Country (2027-2032)
  6. 7.4 Global Age Related Macular Degeneration Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Age Related Macular Degeneration Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Age Related Macular Degeneration Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Age Related Macular Degeneration Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Age Related Macular Degeneration Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Age Related Macular Degeneration Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Regeneron Pharmaceuticals
  2. 8.1.1 Regeneron Pharmaceuticals Company Information
  3. 8.1.2 Regeneron Pharmaceuticals Business Overview
  4. 8.1.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Portfolio
  6. 8.1.5 Regeneron Pharmaceuticals Recent Developments
  7. 8.2 Bayer HealthCare
  8. 8.2.1 Bayer HealthCare Company Information
  9. 8.2.2 Bayer HealthCare Business Overview
  10. 8.2.3 Bayer HealthCare Age Related Macular Degeneration Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer HealthCare Age Related Macular Degeneration Drug Product Portfolio
  12. 8.2.5 Bayer HealthCare Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Age Related Macular Degeneration Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Age Related Macular Degeneration Drug Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Age Related Macular Degeneration Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Roche Age Related Macular Degeneration Drug Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Kanghong Pharma
  26. 8.5.1 Kanghong Pharma Company Information
  27. 8.5.2 Kanghong Pharma Business Overview
  28. 8.5.3 Kanghong Pharma Age Related Macular Degeneration Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Kanghong Pharma Age Related Macular Degeneration Drug Product Portfolio
  30. 8.5.5 Kanghong Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Age Related Macular Degeneration Drug Value Chain Analysis
  2. 9.1.1 Age Related Macular Degeneration Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Age Related Macular Degeneration Drug Sales Mode & Process
  6. 9.2 Age Related Macular Degeneration Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Age Related Macular Degeneration Drug Distributors
  9. 9.2.3 Age Related Macular Degeneration Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst